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Background: Gain of function mutations in B-RAF and N-RAS occur frequently in melanoma, leading to mitogen
activating protein kinase (MAPK) pathway activation, and this pathway is the target of drugs in development. Our
purpose was to study clinical characteristics of patients with mutations in this pathway and to determine activity of
inhibitors of B-RAF and MEK in short term cultures grown from tumors of some of these patients.
Methods: Clinical and pathologic data were collected retrospectively on melanoma patients tested for B-RAF and
N-RAS mutations at the Yale Cancer Center and associations with survival were determined. We studied in vitro
activity of the pan-RAF inhibitor, RAF265, and the MEK inhibitor, MEK162, in 22 melanoma short term cultures. We
further characterized the effect of MEK inhibition on apoptosis and growth of melanoma cultures.
Results: In a cohort of 144 metastatic melanoma patients we found that patients with N-RAS mutant melanoma
had a worse prognosis. These patients were more likely to have brain metastases at the time of presentation with
metastatic disease than their N-RAS-wild-type counterparts. All N-RAS mutant melanoma cultures tested in our
study (n = 7) were sensitive to MEK inhibition162. Exposure to MEK162 reduced ERK1/2 phosphorylation, and
induced apoptosis. Clonogenic survival was significantly reduced in sensitive melanoma cell cultures.
Conclusions: The prognosis of patients with melanoma expressing constitutively active N-RAS is poor, consistent
with studies performed at other institutions. N-RAS mutant melanoma cultures appear to be particularly sensitive to
MEK162, supporting ongoing clinical trials with MEK162 in N-RAS mutated melanoma.
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Melanoma is the leading cause of fatal skin cancer, and in
recent years, the incidence and mortality of melanoma have
increased. Prior to the recent advances in therapy for pa-
tients with stage IV disease, the prognosis of metastatic
melanoma was very poor with a median survival of less
than 12 months [1]. One of the most significant advances
in recent years was the elucidation of the etiological role of
the mitogen activated protein kinase (MAPK) pathway in
melanomagenesis, particularly the roles of mutant B-RAF
and N-RAS [2]. The RAS-RAF-MAPK signaling pathway is
activated in the vast majority of melanomas, either due to
increased growth factor signaling or by genetic alterations
in N-RAS and B-RAF proteins [3]. Thus, the MAPK path-
way is a key therapeutic target, and activation of this* Correspondence: harriet.kluger@yale.edu
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well [4].
Mutations in B-RAF or N-RAS are found in the ma-
jority of melanomas, and are often identified in benign
nevi as well [5,6]. Activating mutations in B-RAF and
N-RAS occur in 40-60% and 15-25% of melanomas, re-
spectively. Several recent studies have examined the as-
sociations between B-RAF and N-RAS mutations and
clinical characteristics and prognosis in patients with
metastatic melanoma [4,7,8]. Patients with N-RAS and
B-RAF mutations have a higher incidence of CNS (cen-
tral nervous system) metastasis at the time of diagnosis
of stage IV disease compared to patients who are wild-
type for B-RAF and N-RAS, and N-RAS mutation status
was identified as an independent predictor of shorter
survival after a diagnosis of stage IV melanoma [9].
While the precise role of B-RAF mutations in oncogen-
esis is unclear, such mutations result in the constitutivel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vascular development in melanoma tumors [10]. Similarly,
mutations in N-RAS cause activation of downstream
serine/threonine kinases (including B-RAF and PI3K),
which promote cell cycle progression, cellular transform-
ation, and enhanced cell survival [11]. B-RAF is an import-
ant therapeutic target, and inhibition of mutant B-RAF has
resulted in antitumor activity and improved survival in pa-
tients with metastatic melanoma expressing constitutively
active B-RAFV600E [12]. Vemurafenib (Roche-Genentech),
an inhibitor of B-RAF kinase with increased selectivity for
mutant B-RAFV600E, was approved in 2011 by the Food
and Drug Administration for treatment of unresectable
melanoma harboring B-RAFV600 mutations [13]. Dabrafe-
nib (GSK2118436, GlaxoSmithKline Pharmaceuticals), an-
other specific inhibitor of mutant B-RAFV600 kinase, was
approved for this indication in 2013, as was Trametinib
(GSK1120212, GlaxoSmithKline Pharmaceuticals), an orally
available and selective inhibitor of MEK1/2 [14,15]. These
three were approved based on improved overall survival
compared to chemotherapy in phase III clinical trials. Thus,
targeting mutant B-RAF and downstream pathway mem-
bers has significantly changed the management of B-RAF
mutant metastatic melanoma.
RAS protein isoforms are the immediate upstream regu-
lators of B-RAF and constitutively activating mutations in
N-RAS are found in 15-25% of metastatic melanomas. RAS
isoforms function as molecular switches in signal transduc-
tion cascades [16]. RAS GTPases activate their downstream
effectors when bound to GTP and become inactivated once
they hydrolyze GTP to GDP [17]. Being catalytically ineffi-
cient, this biochemical reaction requires co-factors, such as
GTPase activating proteins (GAPs). Members of another
group of enzymes, GTP exchange factors (GEFs), are neces-
sary to re-activate RAS by promoting the release of RAS-
bound GDP [18]. GTP then competes with GDP for RAS
binding. Constitutively active mutant RAS molecules lose
the ability to hydrolyse GTP, even in presence of GAPs
[19]. Mutated RAS isoforms are found in 33% of all cancers
[16]. Nevertheless, attempts to develop molecules that tar-
get biological activity of mutant RAS directly have, so far,
been unsuccessful. For instance, attempts have been made
to inhibit RAS using farnesyltransferase inhibitors [20]. Far-
nesylation is a post translational modification that enables
RAS proteins to attach to the cellular membrane, where
they meet their upstream and downstream signaling part-
ners [21]. Farnesyltransferase is responsible for transferring
a farnesyl group from farnesyl pyrophosphate to the pre-
RAS protein. However, use of farneslytransferase inhibitors
in clinical trials yielded disappointing results [22]. Strategies
indirectly modulating the activity of RAS through inhibition
of RAS-GEFs, stimulation of RAS-GAPs and targeted
sensitization of oncogenic RAS to physiological GAP activ-
ity have been proposed (reviewed in [18]). Although B-RAFinhibitors could be hypothetically used in N-RAS mutated
melanoma to target the pathway downstream of N-RAS,
vemurafenib causes paradoxical hyperactivation of MEK–
ERK1/2 signaling, activates C-RAF, and promotes growth
in mutant N-RAS cell lines [23,24]. Thus, alternative targets
are needed to inhibit growth of tumors with N-RAS
mutations.
MEK1/2 are members of the RAS/RAF/MEK/ERK sig-
naling pathway, and inhibition of MEK might result in
decreased pathway activation in N-RAS and B-RAF mu-
tant melanomas. A recent report identified new muta-
tions in N-RAS and MEK as escape mechanisms
through which B-RAF mutant melanomas acquire resist-
ance to B-RAF inhibitors [25]. Combined treatment with
dabrafenib and trametinib was able to overcome resist-
ance in preclinical models and use in patients with B-
RAF mutated tumors resulted in improved progression
free survival [26].
To verify the clinical significance of B-RAF and N-
RAS mutations in our institutional patient cohort we
performed a retrospective analysis of patients with ad-
vanced melanoma who underwent treatment at the Yale
Cancer Center and for whom sequencing for both B-
RAF (exon 15) and N-RAS (exons 1 and 2) mutations
was done. Furthermore, we studied the pre-clinical activ-
ity of a pan-RAF inhibitor, RAF265 (Novartis Pharma-
ceuticals, Basel, Switzerland), and a MEK1/2 inhibitor
MEK162 (Novartis) on a panel of 22 early passage,
patient-derived melanoma cell cultures. We character-
ized the effect of MEK162 on melanoma cell prolifera-
tion, clonogenicity and apoptosis.
Results
Clinical profiles of patients whose tumors harbor N-RAS
and B-RAF mutations
Characteristics of our cohort of 144 patients with stage IV
melanoma are shown in Table 1. Mutations were found in
B-RAF in 43.7%, N-RAS in 27.7%, and 28.4% were wild
type (WT) for both. The majority of B-RAF mutations were
represented by substitution of valine at position 600 to glu-
tamic acid (74.6% were B-RAFV600E) or to lysine (19% were
B-RAFV600K). Substitutions of glutamine 61 accounted for
95% of N-RAS mutations (most frequently Q61R/K/L/H).
The slightly higher percentage of N-RAS mutant melano-
mas in our population than what is commonly reported
may be a result of the relatively small sample size or a re-
flection of local demographics.
Patients with B-RAF mutations tended to be younger;
median age at initial diagnosis of melanoma was 57.6 in
patients with B-RAF mutations, 68.2 in patients with N-
RAS mutations and 66.3 years in patients wild-type for
both (P <0.0001). Our cohort included 22 patients who
received either dabrafenib (N = 1), vemurafenib (N = 19),
a pan-RAF inhibitor (N = 1) or a pan-RAF inhibitor and
Table 1 Clinical and pathological characteristics
Clinical characteristics B-RAF mutated N-RAS mutated Wild type P value
N = 144 N = 63 (43.7) N = 40 (27.7) N = 41 (28.4)
Frequency of mutations V600E 47(74.6) Q61R 16 (40)
V600K 12 (19) Q61K 12 (30)
V600R/L 2 (3.1) Q61L 6 (15)
Unknown 2 (3.1) Q61H 4 (10)
G12D/V 2 (5)
Sex Male 42 (66) 25 (62) 22 (54) 0.21
Female 21 (33) 15 (38) 19 (46)
Median age (years) 57.6 68.2 66.3 <0.0001
LDH Elevated 28 19 20 0.6
Normal 24 6 12
Unknown 11 15 9
M stage M1a 13 8 9 0.3
M1b 11 14 9
M1c 39 18 23
Soft tissue and skin metastasis 23 (37) 28 (70) 17 (41) 0.0025
Lymph node metastasis 29 (46) 30 (75) 25 (61) 0.01
Lung metastasis 41 (65) 24 (60) 27 (66) 0.8
Liver metastasis 25 (39) 11 (27) 17 (41) 0.3
Bone metastasis 17 7 6 0.3
CNS metastasis 31 (49) 16 (40) 16 (39) 0.5
Median survival from diagnosis of stage IV disease 18.3 13.0 19.6 0.17
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anomas appear to have an increased rate of skin and soft
tissue involvement (70%) compared to B-RAF mutated
counterparts and WT patients (37% and 41% respect-
ively, P = 0.0025). The rate of lymph node metastasis was
also noted to be higher in patients with N-RAS muta-
tions (75%) compared to B-RAF mutant and WT pa-
tients (46% and 61%, respectively) (P = 0.01). No
statistically significant difference was seen between the
genotypes and other clinical characteristics, such as M
stage and LDH levels.
Seeing that B-RAF inhibitors can affect survival in pa-
tients with B-RAF mutant melanomas, this group of pa-
tients was removed from the survival analysis. By Cox
univariate analysis we found a trend towards shorter sur-
vival in the N-RAS mutant population, compared to the
B-RAF and WT groups combined (p = 0.12). The median
survival was 13 and 19.6 months, respectively. Kaplan-
Meier survival curves are shown in Figure 1a for the
three groups of patients (BRAF or NRAS mutant or WT
for both) and Figure 1b for the two groups (NRAS com-
pared to BRAF mutant and WT combined) to visually
demonstrate the differences between the groups.
Interestingly, analysis of anatomic sites at the time of
initial diagnosis of stage IV disease revealed a higher rateof brain involvement among B-RAF (16%) and N-RAS
(15%) mutant melanoma patients, compared with pa-
tients with WT disease (2.5%) (P =0.04). With longitu-
dinal follow-up, however, the rate of development of
brain metastases did not differ among the three groups,
possibly because the WT groups lived longer and thus
developed brain metastases over time.In vitro activity of B-RAF and MEK inhibitors in a large
panel of melanoma cultures
To investigate the effect of B-RAF and MEK inhibition
in melanoma cultures, we used RAF265 (a pan-RAF in-
hibitor), MEK162 (a MEK1/2 inhibitor) and the MEK in-
hibitor trametinib. A panel of 22 patient-derived
melanoma cultures was used; the IC50 for RAF265 and
MEK162 are shown in Table 2. This was compared to
the IC50 for trametinib (Additional file 1: Table S1).
Cells were treated with each drug individually at con-
centrations ranging from 1 nM to 1000 nM and ana-
lyzed three days later. As shown in Table 2, the IC50 for
RAF265 ranged from 24 to >10000 nM, 4 to 2004 nM,
and 62 to 2082 nM for WT, B-RAF mutant and N-RAS
mutant cultures, respectively. The IC50 for MEK162
ranged from 10 to >10000 nM, < 1 to 150 nM, and 4 to
Figure 1 Correlation between N-RAS mutation status and survival probability in melanoma patients. Kaplan-Meier survival curves
demonstrating the overall survival from time of diagnosis of stage IV disease. Panel A shows survival curves for all three patient groups, whereas
panel B shows the patients with N-RAS mutations compared to B-RAF and WT combined. Patients with N-RAS mutations had a trend towards
shorter median survival when compared to the non N-RAS WT counterparts (p = 0.12).
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anoma cultures, respectively.
The sensitivity to RAF265 in wild type (2 out of 5) and
N-RAS (2 out of 7) melanoma cultures was low. Two
wild type cultures (YUROB and YUSOC) are sensitive to
both RAF265 and MEK162. Six of ten B-RAF mutant
cultures were sensitive to RAF265, and seven out of ten
were sensitive to MEK162. In N-RAS mutant melanomaTable 2 Patient-derived melanoma cultures with their B-RAF/
and MEK162
Name of the culture Mutation
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Molecular effects of MEK162
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isoforms are the immediate downstream substrates and
best studied effectors of dual specificity kinases MEK1/2.
To assess the effect of MEK1/2 inhibition on ERK1/2 ac-
tivation state (phosphorylation at T202/Y204 sites), mel-
anoma cultures were treated with MEK162 and
compared with untreated controls. We selected one sen-
sitive and one resistant culture in the WT and B-RAF
mutant categories. Seeing that all N-RAS mutant cul-
tures were sensitive to MEK162, we selected two sensi-
tive cultures for these studies. WT (YUVON and
YUROB), B-RAF mutant (YUKSI and YUMAC) and N-Figure 2 Effect of MEK162 treatment on ERK1/2 phosphorylation and
YUROB), B-RAF mutant (YUKSI and YUMAC) and N-RAS mutant (YUDOSO a
MEK162 inhibitor or left untreated for 4 and 24 hours. Western blot analysi
antibodies. (B) The panel of six melanoma cultures was treated with increa
colonies were formed. Colonies were visualized by crystal violet staining an
of treated cells relative to the untreated cells. Each data point represents aRAS mutant (YUDOSO and YUKIM) cells were treated
with increasing doses (10-1000 nM) of MEK162 or left
untreated for 4 and 24 hours. Western blot analysis was
performed using phospho-ERK1/2, total ERK1/2 and β-
actin antibodies, and results are shown in Figure 2A.
In the MEK162 resistant melanoma cultures (YUVON
and YUKSI), the baseline level of phospho-ERK1/2 and
the ratio of phospho-ERK1/2 to total ERK1/2 was lower
compared to sensitive cultures (YUROB, YUMAC,
YUDOSO, YUKIM). In MEK162-sensitive melanomas
exposure to MEK162 resulted in a significant decrease
in the level of ERK1/2 phosphorylation (Figure 2A).clonogenic survival of melanoma cells. (A) WT (YUVON and
nd YUKIM) cells were treated with increasing doses (10-1000 nM) of
s was performed using phospho-ERK1/2, total ERK1/2 and β-actin
sing concentrations of MEK162. Cells were grown until well-defined
d counted. Colonies were counted and data are presented as percent
mean of four independent experiments +/- standard error.
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We next examined the effect of MEK162 on clonogeni-
city of this panel of six melanoma cultures (Figure 2B).
Inhibition of colony formation corresponded well to the
viability studies conducted on cells (Table 2). Among the
sensitive melanoma cultures, YUROB was somewhat re-
sistant at 10 nM MEK162, retaining 80% clonogenicity
of the control level, whereas the ability of other sensitive
cultures to form colonies at this concentration of
MEK162 dropped below 50% of control (see YUMAC,
YUDOSO, and YUKIM). The least inhibition was seen
with the MEK162 resistant YUVON and YUKSI cells.
Induction of apoptosis by MEK162
The MAPK cascade plays a major role in cell survival
and proliferation. Hence, MEK162-mediated inhibition
of MAPK signaling may result in either cell death, or in-
hibition of proliferation, or both. Microscopic assess-
ment of sensitive melanoma cell cultures suggested that
MEK162 treatment affects cell survival (due to abun-
dance of pyknotic cells). Lysates prepared from
MEK162-treated and vehicle-treated cells were resolved
by SDS-PAGE and probed with an antibody detecting a
cleavage product of a known caspase substrate, PARP
(Figure 3A). Cultures were treated with MEK162 (1000Figure 3 MEK162 induces apoptosis in drug-sensitive melanoma cells
nM) or left untreated for 72 hours. Cell lysates were analyzed by western b
Anti-β-actin western blotting was used as a loading control. (B) Cells were
followed by FACS analysis. Viable cells are found in the lower left quadrant
(late apoptotic/necrotic) quadrants; the upper left quadrant represents pyk
cells in the corresponding subpopulation.nM) for 72 hours or left untreated. Cell lysates were ana-
lyzed by western blotting using an antibody recognizing
cleaved PARP. Increased levels of cleaved PARP were
seen in the sensitive cultures (Figure 3A). The most
abundant PARP cleavage was seen in the sensitive cul-
tures, YUMAC, YUDOSO and YUKIM, and to a much
lesser extent in YUROB, whereas no accumulation of
cleaved PARP was detected in the resistant cultures
(YUVON and YUKSI).
To further examine the inhibitory effect of MEK162
on this panel of melanoma cultures (four MEK162 sensi-
tive: YUROB, YUMAC, YUDOSO, YUKIM, and two
MEK162 resistant: YUVON and YUKSI), we assessed
apoptosis by annexin V/propidium iodide labeling.
Annexin V avidly binds to phosphatidylserine, a
phospholipid found exclusively in the intracellular (cyto-
plasmic) leaflet of the cell membrane under normal
physiological conditions but externalized during early
steps of apoptotic death. Propidium iodide is used in this
assay to differentiate between early and late apoptotic
cells, since it cannot penetrate into viable cells posses-
sing an intact membrane. Hence, cells positive for only
fluorophore-conjugated annexinV binding represent a
dying cell population, whereas doubly stained cells rep-
resent a population in late stages of apoptosis. Cells were. (A) A panel of melanoma cultures was treated with MEK162 (1000
lotting using polyclonal antibody recognizing cleaved PARP.
treated as in (A) and collected for annexin V/propidium iodide labeling
, apoptotic cells are in the lower right (early apoptotic) and upper right
notic nuclei. Numbers in each quadrant represent the percentage of
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MEK162 for 72 hours, harvested and doubly stained
with annexin V/propidium iodide and analyzed by flow
cytometry (Figure 3B). The non-apoptotic viable cells
are negative for annexin V and propidium iodide stain-
ing (bottom left quadrants). Cells at early apoptotic stage
show annexin V positive and propidium iodide negative
staining (bottom right quadrants), whereas cells at ad-
vanced stage of apoptosis are stained positively with
annexin V and propidium iodide (upper right quad-
rants). MEK162 induces robust apoptosis (32-47% of
cells were dead or dying) in all sensitive melanoma cul-
tures except YUROB (Figure 3B), consistent with the
PARP cleavage data. Resistance of YUROB to MEK162-
induced apoptosis may reflect a cytostatic effect since
proliferation of this melanoma culture was affected by
the drug (Table 2 and Figure 2B).
Discussion
In this work we studied the clinical characteristics of
metastatic melanoma patients whose tumors harbored
B-RAF and N-RAS mutations. In our relatively small pa-
tient cohort we found a trend towards worse survival
and a greater likelihood of brain metastases at the time
of initial diagnosis in this patient population. This is
consistent with recent interrogation of a larger cohort of
patients from MD Anderson Cancer Center in which
they showed significantly worse prognosis in this popu-
lation [27]. We similarly confirmed that patients with
B-RAF mutated melanomas are younger than N-RAS
mutated counterparts, as previously reported [27,28]. In
addition to brain metastases at the time of initial presen-
tation, we found other differences in distribution of me-
tastases in N-RAS mutant melanoma patients, who are
more likely to develop metastases to subcutaneous tis-
sues and lymph nodes. Mechanistically, we demonstrate
that the MEK inhibitor, MEK162, potently suppresses
proliferation of all short term patient-derived N-RAS
mutant melanoma cultures tested in our study (n = 7),
and this effect is accompanied by robust induction
of caspase-dependent apoptosis. Melanoma cultures
lacking N-RAS mutation show variable sensitivity to
MEK162.
Mutations in B-RAF (50-60%) or N-RAS (15-25%) are
frequently found in sun-exposed melanomas and result
in hyper-activation of the MAPK pathway [29,30]. In-
activation of oncogenic N-RAS Q61K in N-RAS-driven
mouse melanoma model leads to complete tumor re-
gression, implicating N-RAS not only in tumor estab-
lishment, but also in tumor maintenance [5]. While
mutant B-RAF inhibitors have been successfully
developed and approved for the treatment of melanoma,
direct targeting of oncogenic RAS isoforms, including
N-RAS mutants (Q61K/R/L), is challenging. RAS proteinsare small GTPases possessing low catalytic activity.
GTP-bound RAS activates signaling cascades via binding
and stimulating downstream effectors such as RAF,
PI3K, and PLC, whereas the GDP-bound form of RAS is
inactive. Under normal physiological conditions RAS ac-
tivity is strongly dependent on two types of co-factors:
stimulatory RAS GEFs (GTP Exchange Factors) and
RAS inactivating GAPs (GTPase Activating Proteins).
As a result of the oncogenic N-RAS mutations, ineffi-
cient RAS GTPase activity is crippled even further, fa-
voring RAS accumulation in the constitutively active,
GTP-bound state, resulting in the inability of RAS GAPs
to facilitate GTP-hydrolysis [19]. Alternative approaches
aimed at de-activating oncogenic RAS indirectly include
farnesyl-transferase inhibition and interference with
GTP binding [31] or competing out GEF binding [32].
While some of these strategies have already been unsuc-
cessfully tested in clinical trials, others are still being
evaluated at the early pre-clinical stage. Thus, although
oncogenic RAS isoforms have been found in approxi-
mately 33% of all human cancers [33], there are still no
drugs that are able to effectively target these oncogenes
directly or indirectly.
As there are no drugs that directly target N-RAS, we
studied the activity of indirect targeting of downstream
effectors; RAF and MEK. Although B-RAF appears to be
a plausible target in N-RAS mutated melanoma, preclin-
ical studies have consistently shown that selective B-
RAFV600E inhibitors can actually stimulate cell growth
and have detrimental effects in N-RAS mutated melan-
oma [23,24]. One of the mechanisms of the detrimental
effects of specific B-RAF targeting in N-RAS mutant
melanomas is activation of C-RAF and other down-
stream mediations. One potential approach to overcome
this is pan-RAF inhibition. Our pre-clinical studies, how-
ever, using RAF265, suggest that this approach might
not be optimal, as only two of the seven N-RAS mutant
cultures were sensitive to the drug. RAF265 is no longer
in clinical development due to toxicities seen in clinical
trials, and other approaches are therefore warranted.
Targeting the N-RAS mutant melanomas with drugs
that inhibit signal intermediaries downstream of RAF is
an alternative approach. A number of MEK inhibitors
are in clinical use or clinical development. Selumetinib,
another MEK inhibitor, failed to induce clinical re-
sponses in nine melanoma patients whose tumors har-
bored N-RAS mutations [34]. Trametinib has been used
in this population without success; of the nine N-RAS
mutant melanoma patients treated on a phase I trial of
this drug, none has an objective response [35]. However,
objective clinical responses have been seen in over 20%
of 28 N-RAS mutant melanoma patients treated with
MEK162, and stable disease was seen in additional pa-
tients [36]. Due to the small number of samples used in
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MEK162 is superior to trametinib. Very few N-RAS mu-
tant melanoma patients were treated with trametinib
and the two drugs have not been compared in a ran-
domized setting. RECIST criteria used in clinical trials
require 30% tumor reduction to determine a response,
and it is impossible to accurately infer clinical activity
from in vitro sensitivity data. Additional studies are un-
derway in our laboratory to further explore the RAS/
RAF pathway in N-RAS mutant melanomas and deter-
mine mechanisms of sensitivity to the various MEK
inhibitors.
The clinical activity seen with MEK162 in the earlier
phase trial has led to an ongoing phase III randomized
trial in this patient population, NCT01763164. Our pre-
clinical findings of remarkable sensitivity to MEK162 in
all of seven N-RAS mutant cultures further support this
approach. The plasma levels of MEK162 achievable in
patients (600-1000 nM) are well above the IC50s for
N-RAS mutant cultures used in our study (5-13 nM).
Furthermore, we demonstrate induction of apoptosis in
cultures sensitive to MEK162, suggesting that this drug
has cytotoxic effects, in addition to cytostatic effects in
N-RAS mutant cells. The importance of these results is
underscored by the fact that MEK162 is the first targeted
therapy to show clinical activity in patients with N-RAS
mutated melanoma. While targeting of mutant B-RAF is
possible with such drugs as vemurafenib and dabrafenib,
no such targeted therapy is available for patients with N-
RAS mutations, who often have aggressive disease re-
quiring rapid anti-tumor intervention, which might be
accomplished with targeted therapies.
In conclusion, our data support earlier reports show-
ing that patients with melanomas that harbor oncogenic
N-RAS mutations are likely to have shorter overall sur-
vival and have brain metastases at the time of initial
diagnosis. In vitro inhibition of MEK in a panel of
short-term melanoma cultures demonstrated exquisite
sensitivity in all N-RAS mutant cultures, with resultant
induction of apoptosis in sensitive cultures. Although
other MEK inhibitors have failed to demonstrate clinical
activity in N-RAS mutant melanoma, our findings sup-
port further studies of MEK inhibition in this patient
population, particularly with MEK162. Given that early
phase clinical trials with MEK162 did not show activity
in all patients with N-RAS mutant melanomas, predict-
ive biomarker studies are also warranted.
Materials and methods
Patient selection and clinical data collection
With approval of a Yale Institutional Review Board,
retrospective data were collected from charts of patients
treated at the Yale Cancer Center between 2006 and
2010. Only patients for whom B-RAF and N-RASmutation status was available were included in the ana-
lysis. Patient demographics (age, gender), primary tumor
characteristics (depth, ulceration, anatomic location),
and characteristics at the time of stage IV diagnosis (age,
involved sites, serum lactate dehydrogenase [LDH]) were
collected. Staging was determined according to the
American Joint Committee on Cancer (AJCC) Cancer
Staging Manual seventh edition criteria.
Human melanoma cultures
A panel of 22 low-passage, patient-derived melanoma
cultures were obtained from the tissue specimen core of
the Yale SPORE in Skin Cancer. Associated patient infor-
mation is provided in Table 2. Melanoma cultures were
maintained in OptiMEM media (Invitrogen, Carlsbad,
CA) supplemented with 10% heat-inactivated FBS (Invi-
trogen) and antibiotic-antimycotic (penicillin, strepto-
mycin, amphotericin B; Invitrogen). Cells were cultured
at 37°C in a humidified atmosphere of 95% air/5% CO2.
Cell viability assays
For cell viability assays, cells were plated in triplicate in a 96
well microtiter plate (BD Bioscience) and allowed to grow
for 24 hours to an approximate confluence of 30%.
MEK162 and and RAF265 were provided as a gift by
Novartis Pharmaceuticals. Trametinib was purchased from
Selleckchem (Houston, TX). For drug inhibition studies
RAF265, MEK162 and trametinib were used to treat mel-
anoma cells at various concentrations. Cell viability was
evaluated at 72 hours using the CellTiter-Glo™ Luminescent
Cell Viability Assay, according to the manufacturer’s in-
structions (Promega, USA) and luminescence was mea-
sured using a Victor™ X multilabel plate reader (Perkin
Elmer). The IC50 values were determined by the XLfit soft-
ware (MathIQ version 2.2.2, IDBS Inc). Experiments were
conducted three times and the results represent the average
from these independent experiments.
Western blotting and antibodies
To assess the effect of MEK1/2 inhibition on phospho-
ERK1/2 or PARP cleavage, melanoma cells were treated
with MEK162 or DMSO. Cells were lyzed in RIPA buffer
supplemented with phosphatase and protease inhibitors
and protein concentration was determined using
Bradford reagent (BioRad Laboratories, Hercules, CA).
Protein samples were boiled in Laemli buffer, resolved
using 4-20% gradient Criterion™ XT precast gels (BioRad
Laboratories) and blotted onto nitrocellulose mem-
branes. To detect phospho-ERK1/2 levels, membranes
were probed with rabbit polyclonal phospho-ERK1/
2 T202/Y204 antibodies and reprobed with mouse
monoclonal antibody recognizing total ERK1/2 (Cell
Signaling Technology, Danvers, MA). Rabbit polyclonal
antibody raised against cleaved PARP was used to detect
Thumar et al. Molecular Cancer 2014, 13:45 Page 9 of 10
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nology). For loading control, membranes were stripped
in Restore™ Western Blot Stripping Buffer (Thermo
Scientific/Pierce, Rockford, IL) and reprobed using anti-
β-actin mouse monoclonal antibody (Sigma-Aldrich
Corp, St. Louis, MO). Representative results are shown.
Clonogenic survival assays
YUVON, YUROB, YUKSI, YUMAC, YUDOSO and
YUKIM cells were plated at 1,000 per well in six-well
plates to provide an optimal counting density. Cells were
treated with increasing concentrations of MEK162 (0.1
nM – 1000 nM) and cultured for one to two weeks until
well-defined colonies had formed (≥30 cells/colony), re-
placing culture medium every three days. Cells were
fixed and stained with 0.25% w/v crystal violet in 80%
methanol solution. Digital images of six-well plates were
captured, and colonies were counted using ProtoCOL
software (Synbiosis Inc, UK). Data points are an average
of four independent experiments and error bars repre-
sent the standard error of mean (SEM).
Annexin V and propidium iodide labeling
Apoptosis in MEK162-treateded melanoma cells was
measured using annexin V-Alexa Fluor 488 conjugate
apoptosis kit (Invitrogen) according to the manufactur-
er's instructions. Flow cytometry was performed with a
FACScalibur (BD Biosciences), and results were analyzed
with FlowJo software (Tree Star, Inc). Experiments were
conducted twice independently with similar results. Re-
sults of one of the experiments are shown in Figure 3.
Statistical methods
JMP version 5.0 software was used (SAS Institute, Cary,
NC) to analyze the clinical data. Prognostic significance
of parameters was assessed using the Cox proportional
hazards methods and survival curves were generated
using the Kaplan-Meier method. Associations between
clinical/pathological parameters and mutational status
were assessed by analysis of variance and the Chi square
test (χ2).
Additional file
Additional file 1: Patient-derived melanoma cultures with their
B-RAF/N-RAS mutational status and sensitivity to MEK162 and
trametinib.
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